

- Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. *Oral Oncol* 2010; 46:452–456.
- National Institutes of Health Consensus Development Panel. Consensus statement: Oral complications of cancer therapies. *NCI Monogr* 1989;9:3–8.
- Cheng KK, Leung SF, Liang RH, et al. Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life. *Support Care Cancer* 2009;18:1477–1485.
- Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. *Cancer* 2008;113: 2704–2713.
- Barasch A, Peterson DE. Risk factors for ulcerative mucositis in cancer patients: unanswered questions. *Oral Oncol* 2003;9:91–100.
- Dodd MJ, Miaskowski C, Shiba GH, et al. Risk factors for CT-induced oral mucositis: dental appliances, oral hygiene, previous oral lesion, and a history of smoking. *Cancer Invest* 1999;17:278–284.
- Driezen S. Description and incidence of oral complications. *NCI Monogr* 1990;9:1–15.
- Grazziutti ML, Dong L, Miceli MH, et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. *Bone Marrow Transplant* 2006;38:501–506.
- Vokurka S, Steinerova K, Karas M, et al. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. *Bone Marrow Transplant* 2009;44:601–605.
- Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. *J Clin Oncol* 2008;26:1519–1525.
- Sonis ST. Oral complications of cancer therapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. *Cancer: Principles and Practice of Oncology*. 4th ed. Philadelphia: JB Lippincott; 1993: 2385.
- Sonis ST. Mucositis as a biological process: a new hypothesis for the development of CT-induced stomatotoxicity. *Oral Oncol* 1998;34:39–43.
- Woo SB, Sonis ST, Monopoli MM, et al. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. *Cancer* 1993;72:1612–1617.
- McCann S, Schwenkglenks M, Bacon P, et al. The prospective oral mucositis audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. *Bone Marrow Transplant* 2009;43:141–147.
- Vera-Llonch M, Oster G, Ford CM, et al. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. *Support Care Cancer* 2007;15:491–496.
- Shih A, Miaskowski C, Dodd MJ, et al. Mechanisms for radiation-induced oral mucositis and the consequences. *Cancer Nurs* 2003;26:222–229.
- Vera-Llonch M, Oster G, Hagiwara M, et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma: risk factors and clinical consequences. *Cancer* 2006;106:329–336.
- Elting LS, Cooksley CD, Chambers MS, et al. Risk outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. *Int J Radiat Oncology Biol Phys* 2007;68:1110–1120.
- Murphy BA, Beaumont JL, Isitt J, et al. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. *J Pain Symptom Manage* 2009; 38:522–532.
- Bentzen SM. Preventing or reducing late side effects of RT: radiobiology meets molecular pathology. *Nat Rev Cancer* 2006;6:702–713.
- Vissink A, Jansma J, Spijkervet FK, et al. Oral sequelae of head and neck radiotherapy. *Crit Rev Oral Biol Med* 2003;14:199–212.
- Merigo E, Manfredi M, Meleti M, et al. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. *J Oral Path Med* 2005;34:613–617.
- Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. *J Oral Maxillofac Surg* 2004;62:527–534.
- Sonis ST. The pathobiology of mucositis. *Nat Rev Cancer* 2004;4:277–284.
- Sonis ST, O'Donnell KE, Popat R, et al. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. *Oral Oncol* 2004;40:170–176.
- Lalla RV, Pilbeam CC, Walsh SJ, et al. Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. *Support Care Cancer* 2010;18:95–103.
- Logan RM, Gibson RJ, Sonis ST, et al. Nuclear factor- κ B (NF- κ B) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer CT. *Oral Oncol* 2007;43:395–401.
- Fall-Dickson JM, Ramsay ES, Castro K, et al. Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor- α expression in adult oncology patients undergoing hematopoietic stem cell transplantation. *Clin Ther* 2007;29:2547–2561.
- Avivi I, Avraham S, Koren-Michowitz M, et al. Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT. *Bone Marrow Transplant* 2009;43:801–806.
- Lazarus HM, Vogelsang GB, Rowe JM. Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). *Bone Marrow Transplant* 1997;19:577–600.
- Mays JW, Sarmadi M, Moutsopoulos NM. Oral manifestations of systemic autoimmune and inflammatory diseases: Diagnosis and clinical management. *J Evid Base Dent Pract* 2012;12:265–282.
- Granitto MH, Fall-Dickson JM, Norton CK, et al. Review of therapies for the treatment of oral chronic graft-versus-host disease. *Clin J Oncol Nurs* 2013;18:76–81.
- Lloid ME. Oral medicine concerns of the BMT patient. In: Buchsel PC, Whedon MB, eds. *Bone Marrow Transplantation Administrative and Clinical Strategies*. Boston: Jones and Bartlett; 1995: 257.
- Treister NS, Cook EF, Antin J, et al. Clinical evaluation of oral chronic graft-versus-host disease. *Biol Blood Marrow Transplant* 2008;14:110–115.
- Imanguli MM, Swaim WD, League SC, et al. Increased T-bet+ cytotoxic effectors and type 1 interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. *Blood* 2009;113:3620–3630.
- Fall-Dickson JM, Mitchell SA, Marden S, et al. Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease. *Biol Blood Marrow Transplant* 2010;16:948–956.
- Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response criteria working group report. *Biol Blood Marrow Transplant* 2006;12:252–266.
- Meier JK, Wolff D, Pavletic S, et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. *Clin Oral Investig* 2011;15:127–139.
- Treister NS, Stevenson K, Kim H, et al. Oral chronic graft-versus-host disease scoring using the NIH Consensus Criteria. *Biol Blood Marrow Transplant* 2010;16:108–114.
- Bassim CW, Fassil ZH, Mays JW, et al. Validation of the National Institutes of Health chronic GVHD oral mucosal score using component-specific measures. *Bone Marrow Transplant* 2014;49:116–121.
- McGuire DB, Altomonte V, Peterson DE, et al. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. *Oncol Nurs Forum* 1993;20:1493–1502.
- Fall-Dickson JM, Mock V, Berk RA, et al. Stomatitis-related pain in women with breast cancer undergoing autologous hematopoietic stem cell transplant. *Cancer Nurs* 2008;31:452–461.
- Schubert MM, Williams BE, Lloid ME, et al. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. *Cancer* 1992;69:2469–2477.
- Vogelsang GB. How I treat chronic graft-versus-host disease. *Blood* 2001; 97:1196–1201.
- Gaston-Johnsson F. Measurement of pain: the psychometric properties of the Pain-O-Meter, a simple, inexpensive pain assessment tool that could change health care practices. *J Pain Symptom Manage* 1996;12:172–181.
- Brand HS, Bots CP, Raber-Durlacher JE. Xerostomia and chronic oral complications among patients treated with haematopoietic stem cell transplantation. *Br Dent J* 2009;207:E17.
- Imanguli MM, Atkinson JC, Mitchell SA, et al. Salivary gland involvement by chronic graft-versus-host disease: prevalence, clinical significance and recommendations for evaluation. *Biol Blood Marrow Transplant* 2010;16: 1362–1369.
- Nagler R, Barness-Hadar L, Lieba M, et al. Salivary antioxidant capacity in graft versus host disease. *Cancer Invest* 2006;24:269–277.
- Bassim CW, Ambatipudi KS, Mays JW, et al. Quantitative salivary proteomic differences in oral chronic graft-versus-host disease. *J Clin Immunol* 2012;32:1390–1399.
- Berger AM, Kilroy, TJ. Oral complications. In: DeVita VT, Hellman S, Rosenberg SA, eds. *Cancer: Principles and Practice of Oncology*. 6th ed. Philadelphia: JB Lippincott; 1997: 2714.
- Beumer J, Curtis, T, Morris LR. Radiation complications in edentulous patients. *J Prosthet Dent* 1976;36:193–203.
- Beumer J, Zlotow I, Curtis T. Rehabilitation. In: Silverman S. *Oral cancer*. 3rd ed. New York: American Cancer Society; 1990.
- National Institutes of Health, US Department of Health and Human Services. Cancer Therapy Evaluation Program: *Common Terminology Criteria for Adverse Events* (Version 3.0). <http://ctep.cancer.gov/reporting/ctc.html>. Published June 10, 2003. Updated May 17, 2010. Accessed.
- Eilers J, Berger AM, Petersen MC. Development, testing, and application of the oral assessment guide. *Oncol Nurs Forum* 1988;15:325–330.
- World Health Organization. *WHO Handbook for Reporting Results of Cancer Treatment*. Offset publication No. 48. Geneva: World Health Organization; 1979: 15.
- Schubert MM, Sullivan KM, Morton TH, et al. Oral manifestations of chronic graft-versus-host disease. *Arch Intern Med* 1984;144:1591–1595.

57. McGuire DB, Peterson DE, Muller S, et al. The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients. *Cancer Invest* 2002;20:893-903.
58. Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or CT. *Cancer* 1999;85:2103-2113.
59. Sonis ST, Oster C, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. *J Clin Oncol* 2001;19:2201-2205.
60. Schweiger JW. Oral complications following RT: a five-year retrospective report. *J Prosthet Dent* 1987;58:78-82.
61. Elad S, Ackerstein A, Bitan M, et al. A prospective, double-blind phase two study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2006;37:757-762.
62. Zlotolow IM, Berger AM. Oral manifestations of cancer therapy. In: Berger AM, Portnoy RK, Weissman DE, eds. *Principles and Practice of Palliative Care and Supportive Oncology*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2002: 282.
63. Biron P, Sebban C, Goumet R, et al. Research controversies in management of oral mucositis. *Support Care Cancer* 2000;8:68-71.
64. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. *Cancer* 2004;100:2026-2046.
65. Somerfield M, Padberg J, Pfister D, et al. ASCO clinical practice guidelines: Process, progress, pitfalls, and prospects. *Classic Pap Curr Comments* 2000;4:881-886.
66. Wadleigh RG, Redman RS, Graham MI, et al. Vitamin E in the treatment of chemotherapy-induced mucositis. *Am J Med* 1992;92:481-484.
67. Osaki T, Ueta E, Yoneda K, et al. Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (azelastine) with other antioxidants. *Head Neck* 1994;16:331-339.
68. Watanabe T, Ishihara M, Matsuura K. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. *Int J Cancer* 2010;127:1984-1990.
69. Sangthawan D, Phunggrassami T, Sinkitjarumchai W. A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients. *J Med Assoc Thai* 2013;96:69-76.
70. Mansouri A, Hadjibabae M, Iravani M, et al. The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study. *Hematol Oncol* 2012;30:22-26.
71. Kouloulias V, Kouvaris JR, Kokakis JD, et al. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis. *Int J Radiat Oncol Biol Phys* 2004;59:1148-1156.
72. Sasse AD, Clark LG, Sasse EC, et al. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. *Int J Radiat Oncol Biol Phys* 2006;64:784-791.
73. Spencer A, Horvath N, Gibson J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. *Bone Marrow Transplant* 2005;35:971-977.
74. Savarese DM, Savy G, Vahdat L, et al. Prevention of chemotherapy and radiation toxicity with glutamine. *Cancer Treat Rev* 2003;29:501-513.
75. Pytlík R, Benes P, Patorkova M, et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo-controlled study. *Bone Marrow Transplant* 2002;30:953-961.
76. Coughlin-Dickson TM, Wong RM, Negrin RS, et al. Effect of oral glutamine supplementation during bone marrow transplantation. *J Parent Ent Nutr* 2000;24:61-66.
77. Anderson PM, Ramsey NK, Shy Xo, et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. *Bone Marrow Transplant* 1998;22:339-344.
78. Peterson DE, Jones JB, Pettit RC. Randomized, placebo-controlled trial of safinosar for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. *Cancer* 2007;109:322-331.
79. Vidal-Casariago A, Calleja-Fernández A, Ballesteros-Pomar MD, et al. Efficacy of glutamine in the prevention of oral mucositis and acute radiation-induced esophagitis: a retrospective study. *Nutr Cancer* 2013;65:424-429.
80. Aquino VM, Harvey AR, Garvin JH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. *Bone Marrow Transplant* 2005;36:611-616.
81. Peterson D, Petit G. Phase III study: AES-14 in CT patients at risk for mucositis. *Proc Am Soc Clin Oncol* 2003;22:725.
82. Lalla RV, Gordon GB, Schubert M, et al. A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. *Support Care Cancer* 2012;20:1797-1804.
83. Porteder H, Rausch E, Kment G, et al. Local prostaglandin E2 in patients with oral malignancies undergoing chemo and radiotherapy. *J Craniomaxillofac Surg* 1988;16:371-374.
84. Matejka M, Nell A, Kment G, et al. Local benefit of prostaglandin E2 in radioCT-induced oral mucositis. *Br J Oral Maxillofac Surg* 1990;28:89-91.
85. Labor B, Mrcic M, Pavleric A, et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. *Bone Marrow Transplant* 1993;11:379-382.
86. Epstein JB, Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in mucositis associated with RT. *Oral Surg Oral Med Oral Pathol* 1986;62:145-148.
87. Epstein JB, Stevenson-Moore P, Jackson S, et al. Prevention of oral mucositis in RT: a controlled study with benzydamine hydrochloride rinse. *Int J Radiat Oncol Biol Phys* 1989;16:1571-1575.
88. Lever SA, Dupuis LL, Chan SL. Comparative evaluation of benzydamine oral rinse in children with antineoplastic-induced stomatitis. *Drug Intell Clin Pharmacol* 1987;21:359-361.
89. Epstein JB, Silverman S, Paggiarino DA, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. *Cancer* 2001;92: 875-885.
90. Cheng KK, Yuen JK. A pilot study of chlorhexidine and benzydamine oral rinse for the prevention and treatment of irradiation mucositis in patients with head and neck cancer. *Cancer Nurs* 2006;29:423-430.
91. Leborgne JH, Leborgne F, Zubizarreta E, et al. Corticosteroids and radiation mucositis in head and neck cancer: a double-blind placebo-controlled randomized trial. *Radiother Oncol* 1998;47:145-148.
92. Hong JP, Lee SW, Song SY, et al. Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies. *Eur J Cancer* 2009;18:636-641.
93. Girdler NM, Megurk M, Aqual S, et al. The effect of epidermal growth factor mouthwash on cytotoxic-induced oral ulceration: a phase I clinical trial. *Am J Clin Oncol* 1995;18:403-406.
94. Wu HG, Song SY, Kim YS, et al. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind, placebo-controlled prospective phase 2 multi-institutional clinical trial. *Cancer* 2009;115:3699-3708.
95. Kim KI, Kim JW, Lee HJ, et al. Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation. *Am J Hematol* 2013;88:107-112.
96. DeCordi SD, Giorgutti E, Martina S, et al. Gelclair: potentially an efficacious treatment for CT-induced mucositis. *Proceedings from the Italian Antitumor League III Congress of Professional Oncology Nurses*. October 10-12, 2001, Congliano, Italy, (abst).
97. Sonis ST, Costa JW Jr, Evitts SM, et al. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer CT. *Oral Surg Oral Med Oral Pathol* 1992;74:749-755.
98. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to CT for transitional-cell carcinoma of the urothelium. *N Engl J Med* 1988;318: 1414-1422.
99. Bronchud MH, Howell A, Crowther D, et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. *Br J Cancer* 1989;60: 121-125.
100. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. *Blood* 1992;80:1430-1436.
101. Saarlilahi K, Kajanti M, Joensuu T. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. *Int J Radiat Oncology Biol Phys* 2002;2:479-485.
102. Masucci B, Broman P, Kelly C, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. *Med Oncol* 2005;22:247-256.
103. McAleese JJ, Bishop KM, A'Hern R, et al. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. *Br J Radiol* 2006;79:608-613.
104. Ryu JK, Swann S, LeVeque F, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. *Int J Radiat Oncology Biol Phys* 2007;67:643-650.
105. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. *N Engl J Med* 2004;351: 2590-2598.
106. Luthi F, Berwert L, Frosasard V. Prevention of oral mucositis with palifermin in patients treated with high-dose CT and autologous stem cell transplantation: a single center experience. *Blood* 2006;108:843.
107. Nasilowska-Adamska B, Rzepecki P, Manko J, et al. The significance of palifermin (Kepivance) in reduction of oral mucositis (OM) incidence and acute graft versus host disease (aGVHD) in a patient with hematological disease undergoing HSCT. *Blood* 2006;108:840.
108. Nasilowska-Adamska B, Rzepecki P, Manko J, et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2007;40:983-988.

109. Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. *J Clin Oncol* 2011;29:2808–2814.
110. Henke M, Alfonsi M, Foa P, et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. *J Clin Oncol* 2011;29:2815–2820.
111. Rosen LS, Abdi E, David ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. *J Clin Oncol* 2006;24:5194–5200.
112. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. *J Clin Oncol* 2008;26:2489–2496.
113. Vadhan-Raj S, Trent J, Patel S, et al. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. *Ann Intern Med* 2010;153:358–367.
114. Donnelly JP, Bellm LA, Epstein JB, et al. Antimicrobial therapy to prevent or treat oral mucositis. *Lancet Infect Dis* 2003;3:405–412.
115. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. *J Infect Dis* 1995;171:1545–1552.
116. Wahlin BY. Effects of chlorhexidine mouth rinse on oral health in patients with acute leukemia. *Oral Surg Oral Med Oral Pathol* 1989;68:279–287.
117. Dodd MJ, Larson PL, Dibble SL, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. *Oncol Nurs Forum* 1996;23:921–927.
118. Sorensen JB, Skovsgaard T, Bork E, et al. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. *Cancer* 2008;112:1600–1606.
119. Sutherland SE, Browman GP. Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. *Int J Radiat Oncol Biol Phys* 2001;4:917–930.
120. Spijkervet FK, Saene HK, van Saene JJ, et al. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. *J Surg Oncol* 1991;46:167–173.
121. Sharma A, Rath GK, Chaudhary SP, et al. Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. *Eur J Cancer* 2012;48:875–881.
122. Satheeshkumar PS, Chamba MS, Balan A, et al. Effectiveness of triclosan in the management of radiation-induced oral mucositis: a randomized clinical trial. *J Cancer Res Ther* 2010;6:466–472.
123. Svanberg A, Ohm K, Birgegård G. Oral cryotherapy reduces mucositis and improves nutrition—a randomized controlled trial. *J Clin Nurs* 2010;19:2146–2151.
124. Mahoud DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. *J Clin Oncol* 1991;9:449–452.
125. Roewe LK, Loprinzi CL, Lee JK, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-FU-related stomatitis. *Cancer* 1993;72:2234–2238.
126. Cascinu S, Fedeli A, Fedeli SL, et al. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-FU-induced stomatitis. *Oral Oncol Eur J Cancer* 1994;30:234–236.
127. Papadeas E, Naxakis S, Riga M, et al. Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. *Eur J Oncol Nurs* 2007;11:60–65.
128. Katrancic N, Ovayolu N, Ovayolu O, et al. Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy—a randomized controlled trial. *Eur J Oncol Nurs* 2012;16:339–344.
129. Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 2006;37:1031–1035.
130. Salvador P, Azusano C, Wang L, et al. A pilot randomized controlled trial of an oral care intervention to reduce mucositis severity in stem cell transplant patients. *J Pain Symptom Manage* 2012;44:64–73.
131. Svanberg A, Birgegård G, Öhrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy: a randomized controlled trial. *Support Care Cancer* 2007;15:1155–1161.
132. Bensadoun RJ, Ciais G. Radiation- and chemotherapy-induced mucositis in oncology: results of multicenter phase III studies. *J Oral Laser Appl* 2002;2:115–120.
133. Bensadoun RJ, Ciais G, Schubert MM, et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. *Support Care Cancer* 1999;7:244–252.
134. Cowen D, Tardieu C, Schubert M, et al. Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone-marrow transplant: results of a double-blind randomized trial. *Int J Radiat Oncol Biol Phys* 1997;38:697–703.
135. Borst GR, Sonke JJ, den Hollander S, et al. Clinical results of image-guided deep inspiration breath hold breast irradiation. *Int J Radiat Oncol Biol Phys* 2010;78:1345–1351.
136. Genot-Klastersky MT, Klastersky J, Awada F, et al. The use of lower-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies. *Support Care Cancer* 2008;16:1381–1387.
137. Zanin T, Zanin F, Carvalhosa AA, et al. Use of 660-nm diode laser in the prevention and treatment of human oral mucositis induced by radiotherapy and chemotherapy. *Photomed Laser Surg* 2010;26:233–237.
138. Arora H, Pai KM, Maiya A, et al. Efficacy of He-Ne Laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008;105:180–186.
139. Gautam AP, Fernandes DJ, Vidyasagar MS, et al. Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy—a randomized controlled trial. *Support Care Cancer* 2013;21:1421–1428.
140. Gautam AP, Fernandes DJ, Vidyasagar MS, et al. Low level laser therapy for concurrent chemoradiotherapy induced oral mucositis in head and neck cancer patients - a triple blinded randomized controlled trial. *Radiother Oncol* 2012;104:349–354.
141. Mangoni M, Yue X, Morin C, et al. Differential effect triggered by a heparin mimetic of the RGTA family preventing oral mucositis without tumor protection. *Int J Radiat Oncol Biol Phys* 2009;74:1242–1250.
142. Wu SX, Cui TT, Zhao C, et al. A prospective, randomized, multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma. *Radiother Oncol* 2010;97:113–118.
143. Loo WT, Jin LJ, Chow LW, et al. Rhodiola algida improves chemotherapy-induced oral mucositis in breast cancer patients. *Expert Opin Investig Drugs* 2010;19:S91–S100.
144. Elad S, Luboshitz-Shon N, Cohen T, et al. A randomized controlled trial of visible-light therapy for the prevention of oral mucositis. *Oral Oncol* 2011;47:125–130.
145. Yen SH, Wang LW, Lin YH, et al. Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 2012;82:1463–1470.
146. Imanguli M, Pavletic SZ, Guadagnini JP, et al. Chronic graft versus host disease of oral mucosa: review of available therapies. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006;101:175–183.
147. Mays JW, Fassil H, Edwards DA, et al. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. *Oral Diseases* 2013;9:327–346.
148. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. *Bone Marrow Transplant* 2007;40:273–277.
149. Wolff D, Anders V, Corio R, et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs-host disease. *Photodermatol Photoimmunol Photomed* 2004;20:184–190.
150. Epstein JB, Reece DE. Topical cyclosporine A for treatment of oral chronic graft-versus-host disease. *Bone Marrow Transplant* 1994;13:81–86.
151. Eckardt A, Starke O, Stadler M, et al. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. *Oral Oncol* 2004;40:811–814.
152. Albert MH, Becker B, Schuster FR, et al. Oral graft vs host disease in children: treatment with topical tacrolimus ointment. *Pediatr Transplant* 2007;11:306–311.
153. Elad S, Zeevi I, Finke ZJ, et al. Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide—an open, randomized, multicenter study. *Biol Blood Marrow Transplant* 2012;18:134–140.
154. St. John L, Gordon SM, Childs R, et al. Topical thalidomide gel in oral chronic GVHD, and role of *in situ* cytokine expression in monitoring biological activity. *Bone Marrow Transplantation* 2013;48:610–611.
155. National Institutes of Health Clinical Center, National Cancer Institute. Clobetasol for oral graft-versus-host disease. <http://clinicaltrials.gov/ct2/show/NCT01557517>. Accessed (date).
156. Loprinzi CL, Ghosh C, Camoriani J, et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based CT. *J Clin Oncol* 1997;15:1235–1238.
157. Nottage M, McLachlan SA, Brittain MA, et al. Sucralfate mouthwash for prevention and treatment of 5-FU-induced mucositis: a randomized, placebo-controlled trial. *Support Care Cancer* 2003;11:41–47.
158. Scherlacher A, Beaufort-Spontin E. Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment. *HNO* 1990;38:24–28.
159. Epstein JB, Wong FLW. The efficacy of sucralfate suspension in the prevention of oral mucositis due to RT. *Int J Radiat Oncol Biol Phys* 1994;28:693–698.
160. Dodd MJ, Miaskowski C, Greenspan D. Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt and soda mouthwashes. *Cancer Invest* 2003;21:21–33.
161. Innocenti M, Moscatelli C, Lopez S. Efficacy of Gelclair in reducing pain in palliative care patients with oral lesions. Preliminary findings from an open pilot study. *J Pain Symptom Manage* 2001;24:456–457.
162. Barber C, Powell R, Ellis A, et al. Comparing pain control and ability to eat and drink with standard therapy vs Gelclair: a preliminary, double centre, randomised controlled trial on patients with radiotherapy-induced oral mucositis. *Support Care Cancer* 2007;15:427–440.

163. Epstein JB, Truelove EL, Oien H, et al. Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy. *Oral Oncol* 2001;37:632–637.
164. Epstein JD, Epstein JB, Epstein MS, et al. Oral topical doxepin rinse: analgesic effect and duration of pain reduction in patients with oral mucositis due to cancer therapy. *Anesth Analg* 2006;103:465–470.
165. Epstein JB, Epstein JD, Epstein MS, et al. Doxepin rinse for management of mucositis pain in patients with cancer: one week follow-up of topical therapy. *Spec Care Dent* 2009;28:73–77.
166. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl (OTFC) and morphine sulfate immediate release (MSIR). *Pain* 2001;91:123–130.
167. Darwish M, Kirby M, Robertson P, et al. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis. *Clin Drug Invest* 2007;27:605–611.
168. Kim JC, Sohn SK, Kim DH, et al. Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral mucositis in patients receiving stem cell transplantation. *Transplant Proc* 2005;37:4488–4491.
169. Cerchietti LC, Navigante AH, Bonomi MR, et al. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck cancer. *Cancer* 2002;95:2230–2236.
170. Swisher ME, Scheidler VR, Kennedy MJ. A mucositis pain management algorithm: a creative strategy to enhance the transition to ambulatory care. *Oncol Nurs Forum* 1998.
171. Gupta A, Duckles B, Giordano J. Use of sublingual methadone for treating pain of chemotherapy-induced oral mucositis. *J Opioid Manag* 2010;6:67–69.
172. Joseph-Ryan A, Lin F, Samady R. Ketamine mouthwash for mucositis pain. *J Palliat Med* 2009;12:989–991.
173. Huscher A, De Stefani A, Smussi I. Transdermal buprenorphine for oropharyngeal mucositis-associated pain in patients treated with radiotherapy for head and neck cancer. *J Palliat Med* 2010;13:357–358.
174. Atkinson JC, Grisius M, Massey W. Salivary hypofunction and xerostomia: diagnosis and treatment. *Dent Clin North Am* 2005;49:309–326.
175. Agha-Hosseini F, Mirzaei-Dizgah I, Ghavamzadeh L, et al. Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). *Bone Marrow Transplant* 2007;39:431–434.
176. Brizel DM, Wasserman TH, Strnad V, et al. Final report of a phase III randomized trial of amifostine as a radioprotectant in head and neck cancer. Proceedings of the American Society for Therapeutic Radiology and Oncology 41st Annual Meeting. *Int J Rad Onc Biol Phys* 1999, San Antonio, Texas, Oct. 31–Nov. 4, Texas. (abst).